tiprankstipranks
Advertisement
Advertisement

BOLD Stock Latest News

Boundless Bio, Serapha Bio to combine in all-stock merger
The FlyBoundless Bio, Serapha Bio to combine in all-stock merger
11d ago
BOLD
Boundless Bio to Merge with Serapha Bio, Restructure Operations
PremiumCompany Announcements
Boundless Bio to Merge with Serapha Bio, Restructure Operations
11d ago
8K
BOLD
Boundless Bio Shareholders Back Directors and Auditor Appointments
PremiumCompany Announcements
Boundless Bio Shareholders Back Directors and Auditor Appointments
17d ago
8K
BOLD
Boundless Bio Halts Early Cancer Trial, Resetting Expectations for BOLD
PremiumCompany Announcements
Boundless Bio Halts Early Cancer Trial, Resetting Expectations for BOLD
26d ago
BOLD
Boundless Bio reports Q1 EPS (60c), consensus (56c)
PremiumThe Fly
Boundless Bio reports Q1 EPS (60c), consensus (56c)
2M ago
BOLD
Boundless Bio presents preclinical data for BBI-940 therapy at AACR
PremiumThe FlyBoundless Bio presents preclinical data for BBI-940 therapy at AACR
3M ago
BOLD
Boundless Bio Terminates Major Long-Term San Diego Lease
Premium
Company Announcements
Boundless Bio Terminates Major Long-Term San Diego Lease
3M ago
8K
BOLD
Boundless Bio reports Q4 EPS (58c), consensus (52c)
Premium
The Fly
Boundless Bio reports Q4 EPS (58c), consensus (52c)
4M ago
BOLD
Boundless Bio sees cash runway into 2H28
PremiumThe Fly
Boundless Bio sees cash runway into 2H28
4M ago
BOLD
Boundless Bio Advances New Breast Cancer Drug BBI-940 Into First-in-Human Trial
PremiumCompany Announcements
Boundless Bio Advances New Breast Cancer Drug BBI-940 Into First-in-Human Trial
5M ago
BOLD
Boundless Bio announces FDA accepted IND application of BBI-940
PremiumThe Fly
Boundless Bio announces FDA accepted IND application of BBI-940
6M ago
BOLD
Boundless ceases enrollment of Phase 1/2 Potentiate trial of BBI-355, BBI-825
PremiumThe Fly
Boundless ceases enrollment of Phase 1/2 Potentiate trial of BBI-355, BBI-825
6M ago
BOLD
Boundless Bio Terminates Early-Stage BBI-825 Cancer Trial: What Investors Should Know
PremiumCompany AnnouncementsBoundless Bio Terminates Early-Stage BBI-825 Cancer Trial: What Investors Should Know
6M ago
BOLD
Boundless Bio Inc. Reports Q3 2025 Financial Results
Premium
Company Announcements
Boundless Bio Inc. Reports Q3 2025 Financial Results
8M ago
BOLD
Boundless Bio reports Q3 EPS (62c), consensus (58c)
Premium
The Fly
Boundless Bio reports Q3 EPS (62c), consensus (58c)
8M ago
BOLD
Boundless Bio sees cash runway into 1H28
PremiumThe Fly
Boundless Bio sees cash runway into 1H28
8M ago
BOLD
Boundless Bio’s Innovative Cancer Study: A Potential Game-Changer?
PremiumCompany Announcements
Boundless Bio’s Innovative Cancer Study: A Potential Game-Changer?
8M ago
BOLD
Innovative Cancer Treatment Approach and Promising Outlook Drive Buy Rating for Boundless Bio Inc.
PremiumRatings
Innovative Cancer Treatment Approach and Promising Outlook Drive Buy Rating for Boundless Bio Inc.
8M ago
BOLD
PremiumRatings
Hold Rating on Boundless Bio Inc.: Awaiting Clinical Validation of Innovative Therapies
11M ago
BOLD
Boundless Bio price target lowered to $4 from $5 at H.C. Wainwright
PremiumThe FlyBoundless Bio price target lowered to $4 from $5 at H.C. Wainwright
11M ago
BOLD
Premium
Company Announcements
Boundless Bio Reports Q2 2025 Financial Results
11M ago
BOLD
Boundless Bio reports Q2 EPS (70c), consensus (65c)
Premium
The Fly
Boundless Bio reports Q2 EPS (70c), consensus (65c)
11M ago
BOLD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >